Vistagen to Present at Cowen 43rd Annual Health Care Conference
03 March 2023 - 12:30AM
Business Wire
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical
company aiming to transform the treatment landscape for individuals
living with anxiety, depression and other central nervous system
(CNS) disorders, today announced that its Chief Executive Officer,
Shawn Singh, will present and host one-on-one meetings at the Cowen
43rd Annual Health Care Conference taking place March 6 – 8, 2023
in Boston, MA.
Cowen Health Care Conference Details Presentation Date
and Time: Wednesday, March 8, 2023 at 12:50 p.m. Eastern Time
Location: Boston Marriott Copley Place in Boston, MA
The conference incorporates presentations, fireside chats and
innovative panel discussions hosted by members of the Cowen
research team that focus on various aspects of the health care
industry. Investors interested in arranging a one-on-one meeting
during the conference should contact the Cowen 43rd Annual Health
Care Conference coordinator.
About Vistagen
Vistagen (Nasdaq: VTGN) is a late clinical-stage
biopharmaceutical company aiming to transform the treatment
landscape for individuals living with anxiety, depression and other
CNS disorders. The Company is advancing therapeutics with the
potential to be faster-acting, and with fewer side effects and
safety concerns, than those that are currently available for
treatment of anxiety and depression and other CNS disorders.
Several of Vistagen’s product candidates belong to a new class of
drugs known as pherines, which are designed with a novel
rapid-onset mechanism of action that activates chemosensory neurons
in the nasal passages and can impact key neural circuits without
systemic uptake or direct activity on CNS neurons in the brain.
Vistagen is passionate about transforming mental health care and
redefining what is possible in the treatment of anxiety and
depression. Connect at www.Vistagen.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230302005325/en/
Investors: Mark Flather Vice President, Investor Relations (650)
577-3617 mflather@vistagen.com
Media: Nate Hitchings SKDK nhitchings@skdknick.com
Vistagen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From Apr 2024 to May 2024
Vistagen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From May 2023 to May 2024